Meeting
2019 ASCO Annual Meeting
A phase Ia/Ib trial of the anti-PD-L1 human monoclonal antibody (mAb), CS1001, in patients (pts) with advanced solid tumors or lymphomas.
Authors
Lin Shen
Beijing Cancer Hospital, Beijing, China
Lin Shen , Junning Cao , Jin Li , Hongming Pan , Nong Xu , Yan Zhang , Jingru Wang , Yin Wang , Hangjun Dai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Immunotherapy and Tumor Immunobiology
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Antibodies
Clinical Trial Registration Number
NCT03312842
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2526)
DOI
10.1200/JCO.2019.37.15_suppl.2526
Abstract #
2526
Poster Bd #
170
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
First-in-human study of KHK2455, a long-acting, potent and selective indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor, in combination with mogamulizumab (Moga), an anti-CCR4 monoclonal antibody, in patients (pts) with advanced solid tumors.
First Author: Timothy Anthony Yap
Poster
2023 ASCO Annual Meeting
IMM01 plus tislelizumab in patients with advanced solid tumors and lymphoma: An open-label, multicenter, phase 1b/2 dose escalation and expansion study (IMM01-04).
First Author: Zhengbo Song
Poster
2023 ASCO Annual Meeting
Subcutaneous amivantamab (ami) in patients (pts) with advanced solid malignancies: The PALOMA study—Updated safety and identification of the recommended phase 2 dose.
First Author: Anna Rachel Minchom
Poster
2023 ASCO Annual Meeting
Debio 0123-101: A phase 1 trial of Debio 0123 in combination with carboplatin in advanced solid tumors—Safety, pharmacokinetic, and preliminary antitumor activity data.
First Author: Hans Gelderblom